153 related articles for article (PubMed ID: 31421468)
1. Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis.
Sun XS; Lin C; Liang YJ; Chen QY; Tang LQ; Mai HQ
Oral Oncol; 2019 Oct; 97():31-36. PubMed ID: 31421468
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.
Jin Y; An X; Cai YC; Cao Y; Cai XY; Xia Q; Tan YT; Jiang WQ; Shi YX
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1545-51. PubMed ID: 21842218
[TBL] [Abstract][Full Text] [Related]
3. Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.
Sun XS; Liang YJ; Li XY; Liu SL; Chen QY; Tang LQ; Mai HQ
Drug Des Devel Ther; 2019; 13():3207-3216. PubMed ID: 31686783
[TBL] [Abstract][Full Text] [Related]
4. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
5. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
Jeon HL; Oh IS; Baek YH; Yang H; Park J; Hong S; Shin JY
J Bone Miner Metab; 2020 Mar; 38(2):254-263. PubMed ID: 31673791
[TBL] [Abstract][Full Text] [Related]
9. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
10. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid combined with chemotherapy in non-small cell lung cancer with bone metastasis.
Zhang J; Wang LYJGJZYPM
J BUON; 2021; 26(3):830-836. PubMed ID: 34268942
[TBL] [Abstract][Full Text] [Related]
13. Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.
Hortobagyi GN; Zheng M; Mohanlal R
Oncologist; 2019 Feb; 24(2):178-184. PubMed ID: 30297386
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
17. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Hu Z; Tian Y; Li W; Ruan Y; Zeng F
Support Care Cancer; 2020 Jul; 28(7):3291-3301. PubMed ID: 31754835
[TBL] [Abstract][Full Text] [Related]
19. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
20. Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study.
Lelièvre L; Clézardin P; Magaud L; Roche L; Tubiana-Mathieu N; Tigaud JD; Topart D; Raban N; Mouret-Reynier MA; Mathevet P
Clin Breast Cancer; 2018 Dec; 18(6):e1311-e1321. PubMed ID: 30098917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]